BioXcel Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $4.46M, a 3180.88% increase year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $1.47M, a 205.41% increase year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $49.08M, a 10734.00% increase year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $136.00K, a 97.44% decline year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $55.36M, a 457.73% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $9.93M, a 62.14% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $26.22M.
- BioXcel Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $100.99M, a 60.52% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $4.46M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.47M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $55.36M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $49.08M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $136.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $481.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $9.93M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $453.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $5.31M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $3.71M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $26.22M 10-K · filed 2025-03-28 | |
| 2023-03-31 | $23.92M 10-Q · filed 2024-11-14 | |
| 2021-12-31 | $100.99M 10-K · filed 2023-03-16 | |
| 2021-06-30 | $101.03M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $255.78M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $187.01M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $68.81M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $17.81M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $17.50M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $230.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $1.95M 10-K · filed 2020-03-09 | |
| 2018-03-31 | $1.95M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |